Clinical Trial

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Study acronym: PAZOGLIO
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2015-01-05; most recent amendment 2026-04-30.
Status change: Recruiting → Active, Not Recruiting 2026-04-30
Status change: Active, Not Recruiting → Recruiting 2023-02-13
Status change: Recruiting → Active, Not Recruiting 2020-12-17
Trial Details
NCT Number NCT02331498
Lead Sponsor Centre Antoine Lacassagne
Collaborators: GlaxoSmithKline
Conditions Glioblastoma Multiforme
Enrollment 51 participants
Start Date 2015-06
Primary Completion 2027-02 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-06